March 23, 2020 – COVID-19
Please read carefully for information on approved policy exceptions, additional clarifications, and a note-to-file document
Do it right. Do it better.
Beating cancer isn't easy. Neither is running a clinical trial. We need to do it right and do it better.
At the Dana-Farber/Harvard Cancer Center, our investigators are renowned for cutting-edge and ground-breaking science. The ODQ brings that same innovative spirit to clinical research quality and operations.
Let's move research forward. The fight against cancer is too important not to.
ODQ News & Updates
-
-
March 18, 2020 – COVID-19
Clarifications regarding DF/HCC consent requirements for human subject oncology research in response to shared Partner's communications
-
March 14, 2020 – COVID-19
To all staff participating in human subject research at DF/HCC: Below is some additional information to clarify what changes require prospective review and approval by the DFCI IRB in light of the steps we...